prostaglandins E2
Phase 3Small molecule
prostaglandins E2 is one of 18 small molecule programs targeting Fetal Growth Restriction. It is currently in Phase 3.
2
Indications
2
Total Trials
0
Active Trials
17
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
15 competitors in Fetal Growth Restriction
#DrugCompanyPhaseTrials
1Heparin Sodium
BBaxter Healthcare Corporation
Approved
Bayer Aspirin
BayerPhase 3
Cervidil
PfizerPhase 3
Lovenox
SanofiPhase 3
Viagra
VViatris Specialty LLC
Phase 3
Circadin
NNeurim Pharmaceuticals Ltd.
Phase 3
Genotropin
EMD SeronoPhase 3
Low-Molecular-Weight Heparin
Daiichi SankyoPhase 3
Sildenafil ODT
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
prostaglandins E2
TTel-Aviv Sourasky Medical Center
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for prostaglandins E2. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- TTel-Aviv Sourasky Medical Center